The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended three novel medicines for approval at its ...

Regeneron Pharmaceuticals (NASDAQ:REGN) said the European Medicines Agency’s Committee for Medicinal Products for Human Use ...

Eli Lilly and Co. to discover, develop and commercialize molecular glue therapeutics for oncology. “It’s a really important deal, especially given the discovery of Trueglues is something Magnet is ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human ...

Regeneron on Friday said the recommendation covers adults with adults with relapsed and refractory multiple myeloma who have received at least three prior therapies, including a proteasome inhibitor, ...

Pharmaceuticals announced that the European Medicines Agency’s, EMA, Committee for Medicinal Products for Human Use, CHMP, has ...

MILWAUKEE, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Brady Corporation (NYSE:BRC) ("Brady” or "Company”) announced that Anne De Greef-Safft has joined its Board of Directors, effective February 25, 2025.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion ...

Lenacapavir is a twice-yearly injectable medication designed to be used as pre-exposure prophylaxis (PrEP). The FDA is giving ...

Regeneron Pharmaceuticals' fourth quarter results beat my and Wall Street analysts' expectations. See why REGN stock is a top pick for long-term investors.

Individual paraproteinemic disorders exhibit distinct neuropathic phenotypes, often with characteristic, identifiable clinical features. Frequently, prognoses are not well-defined, and in many ...

Am J Health Syst Pharm. 2007;64(17):1799-1807. Despite its efficacy, thalidomide's use has been limited by the agent's toxicity profile. In addition to the widely known teratogenic effects of ...